Literature DB >> 17638205

Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).

Patricia Mwebaze Songa1, Barbara Castelnuovo, Estella Birabwa Mugasha, Ponsiano Ocama, Andrew Kambugu.   

Abstract

We describe 24 Ugandan patients with human immunodeficiency virus infection who developed symptomatic hyperlactatemia associated with the use of nucleoside analogues. All patients were receiving combination therapy that contained stavudine. The median serum lactate level was 6.6 mmol/L. All patients had their antiretroviral treatment regimen discontinued. Hospital admission was required for 5 patients. Five patients died.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638205     DOI: 10.1086/520023

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia?

Authors:  Barbara Castelnuovo; Agnes Nanyonjo; Moses Kamya; Ponsiano Ocama
Journal:  Afr Health Sci       Date:  2008-06       Impact factor: 0.927

2.  Fatal toxicity from symptomatic hyperlactataemia: a retrospective cohort study of factors implicated with long-term nucleoside reverse transcriptase inhibitor use in a South African hospital.

Authors:  Liza Leung; Douglas Wilson; Alex F Manini
Journal:  Drug Saf       Date:  2011-06-01       Impact factor: 5.606

3.  Short communication: Severe symptomatic hyperlactatemia among HIV type 1-infected adults on antiretroviral therapy in Côte d'Ivoire.

Authors:  Albert Minga; Charlotte Lewden; Lambert Dohoun; Yao Abo; Arlette Emieme; Ali Coulibaly; Roger Salamon; Serge Eholié; Xavier Anglaret; Christine Danel
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09       Impact factor: 2.205

4.  Hyperlactatemia and concurrent use of antiretroviral therapy among HIV infected patients in Uganda.

Authors:  M Waiswa; B B Byarugaba; P Ocama; H Mayanja-Kizza; E Seremba; S Ganguli; M Crowther; R Colebunders
Journal:  Afr Health Sci       Date:  2012-09       Impact factor: 0.927

5.  Reduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme: a retrospective observational study.

Authors:  Charlotte Schutz; Andrew Boulle; Dave Stead; Kevin Rebe; Meg Osler; Graeme Meintjes
Journal:  AIDS Res Ther       Date:  2010-05-26       Impact factor: 2.250

6.  HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa.

Authors:  Christopher J Hoffmann; Salome Charalambous; Katherine L Fielding; Craig Innes; Richard E Chaisson; Alison D Grant; Gavin J Churchyard
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

7.  Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.

Authors:  Pauline Byakika-Kibwika; Mohammed Lamorde; Francis Kalemeera; Antonio D'Avolio; Sciandra Mauro; Giovanni Di Perri; Mairin Ryan; Harriet Mayanja-Kizza; Saye Khoo; David Back; Marta Boffito; Concepta Merry
Journal:  J Antimicrob Chemother       Date:  2008-07-18       Impact factor: 5.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.